Calquence (acalabrutinib) / AstraZeneca  >>  Phase 2
Welcome,         Profile    Billing    Logout  

105 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Calquence (acalabrutinib) / AstraZeneca
NCT02387762: ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

Completed
2a
31
US
acalabrutinib, methotrexate, Placebo
Acerta Pharma BV
Rheumatoid Arthritis
05/16
06/16
ACTRN12621000507886: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 15 substudies 33-34: Durvalumab plus acalabrutinib

Recruiting
2
32
 
The University of Sydney, Office for Health and Medical Research, Leukaemia Foundation , Tour de Cure
Cancer, High grade B cell lymphoma
 
 
NCT02570711 / 2015-003428-30: Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

Terminated
2
3
US
ACP-196, acalabrutinib, Nab-paclitaxel, ABRAXANE, Gemcitabine, Gemzar
Acerta Pharma BV
Metastatic Pancreatic Cancer
04/16
04/16
KEYNOTE144, NCT02362048: ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

Completed
2
77
US
ACP-196, ACP-196 in combination with pembrolizumab
Acerta Pharma BV, Merck Sharp & Dohme LLC
Metastatic Pancreatic Cancer
03/17
03/17
KEYNOTE143, NCT02351739: Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer

Checkmark Completion of P2 trial of acalabrutinib + pembrolizumab for platinum-resistant urothelial bladder cancer
Jun 2018 - Jun 2018: Completion of P2 trial of acalabrutinib + pembrolizumab for platinum-resistant urothelial bladder cancer
Completed
2
78
US
pembrolizumab, ACP-196 in combination with pembrolizumab
Acerta Pharma BV, Merck Sharp & Dohme LLC
Metastatic Urothelial Carcinoma
02/18
04/18
KEYNOTE166, NCT02448303: Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer

Completed
2
74
US
Pembrolizumab, Keytruda, Acalabrutinib, ACP-196
Acerta Pharma BV, Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
03/18
06/18
KEYNOTE147, NCT02454179: Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma

Completed
2
78
US
pembrolizumab, Keytruda, Acalabrutinib, ACP-196
Acerta Pharma BV, Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of the Head and Neck
05/18
07/18
KEYNOTE191, NCT02537444: Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer

Hourglass Nov 2018 - Dec 2018 : From KEYNOTE191 trial for recurrent ovarian cancer
Completed
2
78
US
Acalabrutinib, ACP-196, acalabrutinib and pembrolizumab combination
Acerta Pharma BV, Merck Sharp & Dohme LLC
Ovarian Cancer
07/18
10/18
2017-004401-40: A trial of CHOP-R therapy with or without acalabrutinib in patients with newly diagnosed Richter's Syndrome

Not yet recruiting
2
105
Europe
Cyclophosphamide, Acalabrutinib, Doxorubicin, Vincristine, Prednisolone, Rituximab, ACP-196, Powder and solvent for solution for injection/infusion, Capsule, hard, Concentrate and solvent for solution for infusion, Solution for injection, Tablet, Solution for infusion, Cyclophosphamide, Acalabrutinib, Vincristine, Prednisolone, Rituximab
University of Birmingham, Bloodwise, Acerta
Richter's Syndrome, A rare type of non-hodgkin lymphoma, Diseases [C] - Cancer [C04]
 
 
2018-003465-33: Acalabrutinib in CLL and MCL patients subjected to allogeneic hematopoietic stem cell transplantation (alloSCT). Zastosowanie akalabrutynibu u chorych z przewlekłą białaczką limfocytową lub chłoniakiem z komórek płaszcza poddanych allogenicznemu przeszczepieniu komórek macierzystych.

Not yet recruiting
2
40
Europe
acalabrutinib, ACP-196, Capsule, hard, Calquence
Polish Lymphoma Research Group - PLRG, Acerta Pharma, LLC
Mantle Cell Lymmphoma (MCL)Chronic Lymphocytic Leukaemia (CLL) Przewlekła białaczka limfocytowa (CLL)Chłoniak z komórek płaszcza (MCL), Mantle Cell Lymmphoma (MCL)Chronic Lymphocytic Leukaemia (CLL) Przewlekła białaczka limfocytowa (CLL)Chłoniak z komórek płaszcza (MCL), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
ACE-WM-001, NCT02180724 / 2014-003212-36: An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Hourglass Jan 2020 - Dec 2020 : In Waldenstrom microglobulinemia
Checkmark In Waldenström Macroglobulinemiain
Dec 2019 - Dec 2019: In Waldenström Macroglobulinemiain
Active, not recruiting
2
107
Europe, US
Acalabrutinib (ACP-196), Acalabrutinib
Acerta Pharma BV
Waldenström Macroglobulinemia (WM)
10/19
12/26
NCT03623373: Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Active, not recruiting
2
13
US
Bendamustine, Treanda, Bendeka, Rituximab, Rituxan, Rituxan Hycela, Acalabrutinib, Calquence®, Cytarabine, Cytosar-U, Leukapheresis, Peripheral blood, Oral rinse, Bone marrow collection
Washington University School of Medicine, Acerta Pharma BV
Mantle Cell Lymphoma
02/20
02/25
2020-001736-95: A Phase 2 Study for the Treatment of COVID 19 in Hospitalised Patients

Ongoing
2
825
Europe
Bemcentinib, MEDI3506, acalabrutinib, Zilucoplan, Heparin, TD139, BGB324, MEDI3506, ACP-196, Capsule, hard, Solution for injection, Solution for injection in pre-filled syringe, Inhalation powder, Heparin
University Hospital Southampton NHS Foundation Trust
COVID 19, COVID 19, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2020-001644-25: A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19

Ongoing
2
428
Europe
acalabrutinib, ACP-196, Capsule, hard
Acerta Pharma B.V., ACERTA PHARMA BV, Acerta Pharma B.V., AstraZeneca AB
Subjects with life-threatening COVID-19 symptoms, Subjects with life-threatening COVID-19 symptoms, Diseases [C] - Virus Diseases [C02]
 
 
15-H-0016, NCT02337829: Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Hourglass Jan 2020 - Dec 2021 : From trial for r/r and treatment naïve del 17p CLL/SLL
Checkmark In r/r CLL/SLL
Dec 2017 - Dec 2017: In r/r CLL/SLL
Active, not recruiting
2
48
US
Acalabrutinib (Arm A), ACP-196, Acalabrutinib (Arm B)
Acerta Pharma BV, National Institutes of Health (NIH)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/20
04/26
2019-004337-17: Behandeling van chronische lymfatische leukemie met venetoclax en acalabrutinib bij terugkeer van de ziekte na eerdere behandeling met venetoclax in combinatie met immuuntherapie Retreatment of CLL with venetoclax and acalabrutinib after relapse after first line venetoclax treatment combined with immunotherapy for chronic lymphocytic leukemia (CLL or SLL)

Ongoing
2
60
Europe
venetoclax 10 mg, venetoclax 50 mg, venetoclax 100 mg, Acalabrutnib, Tablet, Capsule, hard, Venclyxto
HOVON Foundation, AbbVie B.V., AstraZeneca BV
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04]
 
 
ACE-CL-208, NCT02717611 / 2015-005317-68: A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Hourglass Jan 2020 - Dec 2020 : From ACE-CL-208 trial in r/r CLL
Active, not recruiting
2
60
Europe, US, RoW
ACP-196 (acalabrutinib), Acalabrutinib
Acerta Pharma BV
Chronic Lymphocytic Leukemia
10/20
09/26
CALAVI US, NCT04380688: Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

Completed
2
62
US
Acalabrutinib
AstraZeneca, Acerta Pharma BV
COVID-19
11/20
11/20
CALAVI, NCT04346199: Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

Completed
2
177
Europe, Japan, RoW
Acalabrutinib
AstraZeneca, Acerta Pharma BV
COVID-19
11/20
11/20
ACE-LY-004, NCT02213926 / 2014-002117-28: An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Checkmark Approved for 2L MCL
Oct 2019 - Oct 2019: Approved for 2L MCL
Checkmark Long-term follow-up data ACE-LY-004 trial in relapsed or refractory MCL
Dec 2018 - Dec 2018: Long-term follow-up data ACE-LY-004 trial in relapsed or refractory MCL
Checkmark For r/r/ mantle cell lymphoma in ASH 2017 [Screen shot]
More
Active, not recruiting
2
124
Europe, US, RoW
ACP-196 (acalabrutinib)
Acerta Pharma BV
Mantle Cell Lymphoma (MCL)
12/20
09/26
CLL2-BAAG, NCT03787264 / 2017-003133-28: Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

Completed
2
46
Europe
Bendamustine, Obinutuzumab, GA101, Gazyvaro, Acalabrutinib, ACP-196, Calquence, Venetoclax, ABT-199, Venclyxto
German CLL Study Group
Chronic Lymphoid Leukemia
02/21
09/23
2018-001850-80: Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma

Not yet recruiting
2
80
Europe
acalabrutinib, Mabthera, Capsule, hard, Concentrate for solution for infusion, Mabthera
Skåne University Hospital, Nordic Lymphoma Group, Astra Zeneca
Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma (MCL), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2019-004396-38: Clinical study of acalabrutinib and tafasitamab in previously treated marginal zone lymphoma

Not yet recruiting
2
24
Europe
Acalabrutinib, Tafasitamab, MOR00208, Capsule, hard, Powder and solvent for concentrate for solution for infusion, Minjuvi
IELSG - International Extranodal Lymphoma Study Group, IELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP, Astra Zeneca AG, Incyte Bioseciences International Sàrl, Incyte Biosciences International Sàrl, AstraZeneca AG
Marginal Zone Lymphomas refractory to or in first or greater relapse after prior systemic therapy, Previously treated marginal zone lymphomas, Diseases [C] - Cancer [C04]
 
 
NCT04189952: Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

Terminated
2
2
US
Acalabrutinib, ACP-196, Rituximab, Rituxan, Ifosfamide, Ifex, Isophosphamide, Carboplatin, Paraplatin, Etoposide, Etopophos, Toposar, VePesid
University of Miami, AstraZeneca
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Marginal Zone Lymphoma
06/21
03/22
2020-006081-36: STop and restart Acalabrutinib In fRail patients with previously untreated CLL (STAIR) Arrêt et reprise de l’Acalabrutinib chez les patients fragiles présentant une leucémie lymphoîde chronique non précédemment traitée (STAIR)

Not yet recruiting
2
160
Europe
ACALABRUTINIB, Capsule, CALQUENCE
FILO, ASTRAZENECA
Chronic lymphoid leukemia leucémie lymphoide chronique, fRail patients with previously untreated CLL Patients fragiles atteints d'une LLC non précédemment traitée, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2020-002142-17: Evaluation of a treatment with acalabrutinib in very old (≥80 years) or frail patients with chronic lymphocytic leukemia Beurteilung einer Therapie mit Acalabrutinib bei sehr alten (≥80 Jahre) oder gebrechlichen Patienten mit chronischer lymphatischer Leukämie

Not yet recruiting
2
53
Europe
Acalabrutinib/ ACP-196, Capsule, hard + tablet, Calquence
University of Cologne, AstraZeneca
Patients with CLL requiring treatment, Patients with chronic lymphocytic leukaemia in need of treatment, Diseases [C] - Cancer [C04]
 
 
ACTRN12619000990123: A study to look at the safety and efficacy of Acalabrutinib and Rituximab followed by chemo with or without Autologous stem cell transplant (ASCT) and maintenance Acalabrutinib and Rituximab in fit patients with previously untreated mantle cell lymphoma.

Active, not recruiting
2
44
 
Australasian Leukaemia and Lymphoma Group, Acerta
Mantle cell Lymphoma
 
 
2020-003876-42: Assessing a ctDNA and PET-oriented therapy in patients with DLBCL Aggiustamento terapeutico basato su PET/TAC e DNA tumorale circolante in pazienti con linfoma diffuso a grandi cellule B

Not yet recruiting
2
260
Europe
Acalabrutinib, [ACP-196], Capsule, hard
SAKK, AstraZeneca
Disseminated large B cell lymphoma Linfoma diffuso a grandi cellule B, Disseminated large B cell lymphoma Linfoma diffuso a grandi cellule B, Diseases [C] - Cancer [C04]
 
 
NCT04094142: Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Checkmark Data for r/r aggressive B-cell lymphoma
Jun 2020 - Jun 2020: Data for r/r aggressive B-cell lymphoma
Completed
2
66
RoW
Acalabrutinib, Lenalidomide, Rituximab
Seoul National University Hospital
Non-hodgkin Lymphoma,B Cell
05/22
05/22
UTX-TGR-208, NCT04016805: Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Terminated
2
41
US
Ublituximab, TG-1101, Umbralisib, TGR-1202, Ibrutinib, Imbruvica, Venetoclax, Venclexta, Acalabrutinib Oral Capsule, Calquence
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia
05/22
05/22
NCT04337827: Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder

Terminated
2
6
US
Rituximab, Rituxan, Mabthera, Acalabrutinib, ACP-196, CT scans
Deepa Jagadeesh
Post-transplant Lymphoproliferative Disorder
06/22
12/22
NCT05038904: Preventing Anaphylaxis With Acalabrutinib

Completed
2
10
US
Acalabrutinib, Calquence
Johns Hopkins University, AstraZeneca
Food Allergy, Food Allergy Peanut
12/22
12/22
NCT04685915: Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

Withdrawn
2
0
NA
Ibrutinib, Imbruvica, Copanlisib, Aliqopa, Acalabrutinib, Calquence
Inhye Ahn, Bayer
Chronic Lymphocytic Leukemia (CLL)
03/23
03/28
CLL-Frail, NCT04883749: Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL

Active, not recruiting
2
53
Europe
Acalabrutinib, Calquence, ACP-196
German CLL Study Group
Chronic Lymphoid Leukemia
07/23
12/24
NCT03736616: Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Recruiting
2
47
US
Carboplatin, Ifosfamide, Etoposide, VP-16, Rituximab, Rituxan, Carmustine, BCNU, Cytarabine, ARA-C, Melphalan, Autologous HSCT, Autologous Hematopoeitic Stem Cell Transplantation, Acalabrutinib
Swedish Medical Center, Acerta Pharma BV
Diffuse Large B Cell Lymphoma
09/23
09/23
NCT04783415: Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Hourglass Jul 2023 - Dec 2023 : From trial in combination with Utuxin and Ukoniq for 1L MCL
Active, not recruiting
2
12
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Ublituximab, LFB-R603, TG-1101, TG-20, TGTX-1101, Umbralisib, 2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one, RP-5264, RP5264, TGR-1202
City of Hope Medical Center, National Cancer Institute (NCI)
Mantle Cell Lymphoma
07/22
09/25
NCT04566887: Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

Active, not recruiting
2
54
Canada
Acalabrutinib, R-CHOP chemotherapy
University Health Network, Toronto
Mantle Cell Lymphoma
09/23
11/28
NCT04657094: Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

Active, not recruiting
2
4
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence
City of Hope Medical Center, National Cancer Institute (NCI)
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Warm Antibody Autoimmune Hemolytic Anemia
04/23
12/24
NCT03863184: Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Hourglass Dec 2022 - Dec 2022 : Presentation of data from Phase 2 trial in combination with Lenalidomide and Rituximab for 1L MCL at ASH 2022
Active, not recruiting
2
35
US
Acalabrutinib, CALQUENCE, ACP-196, Lenalidomide, Revlimid, Rituximab, Rituxan
Weill Medical College of Cornell University, AstraZeneca, Celgene Corporation
Mantle Cell Lymphoma
09/24
09/27
NCT04883437: Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Recruiting
2
49
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Emory University, AstraZeneca, National Cancer Institute (NCI)
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Lymphoproliferative Disorder, Mantle Cell Lymphoma, Marginal Zone Lymphoma
01/25
01/26
NCT03788291: Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Completed
2
39
US
Acalabrutinib, Rituximab
University of Rochester
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
05/23
05/23
NCT03946878: Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Active, not recruiting
2
32
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive, CD5 Positive, FCER2 Negative, Pleomorphic Variant Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, t(11;14)(q13;q32)
02/26
02/26
NCT03580928: Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

Hourglass Dec 2022 - Dec 2022 : Presentation of data from Phase 2 trial in combination with Venetoclax and Obinutuzumab for 1L CLL at ASH 2022
Active, not recruiting
2
72
US
Venetoclax, Venclexta, Obinutuzumab, Gazyva, Acalabrutinib, Calquence
Dana-Farber Cancer Institute, AstraZeneca, Genentech, Inc., National Institutes of Health (NIH), National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia (CLL)
04/24
12/27
ACALLO, NCT04716075: Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

Active, not recruiting
2
25
Europe
Acalabrutinib 2x100 MG Oral Capsule + alloSCT
Polish Lymphoma Research Group, AstraZeneca
Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease, Mantle Cell Lymphoma, Adverse Event, Response Rate
06/24
09/24
STAIR, NCT04963946: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia

Recruiting
2
160
Europe
Stop ACA, ACA Continuation
French Innovative Leukemia Organisation
Untreated Chronic Lymphocytic Leukemia
01/26
08/28
19-C-0116, NCT04002947: Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Recruiting
2
132
US
DA-EPOCH, Rituximab, CHOP, Acalabrutinib
National Cancer Institute (NCI)
Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL, NHL
05/25
03/29
NCT04505254: Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Recruiting
2
60
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/25
06/25
NCT04626791: Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Recruiting
2
45
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Mantle Cell Lymphoma
08/24
08/28
NCT05583149: Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Recruiting
2
27
US
ACALABRUTINIB, Calquence, LISOCABTAGENE MARALEUCEL, Breyanzi, Lymphodepleting chemotherapy, cyclophosphamide and fludarabine
Patrick C. Johnson, MD, AstraZeneca
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
03/25
03/29
NCT04484012: Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recruiting
2
36
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T Cells, CD19R(EQ)28zeta/EGFRt+ Naive and Memory T Cells, CD19R(EQ)28zetaEGFRt+ Tn/mem Cells
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
12/24
12/24
Benefit VA, NCT06520098: A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Not yet recruiting
2
100
US
Venetoclax, VENCLEXTA, Ibrutinib, Acalabrutinib, Zanubrutinib, IMBRUVICA, CALQUENCE, BRUKINSA
VA Office of Research and Development
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/29
12/29
NCT05388006: Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting
2
30
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Mayo Clinic
Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
11/24
11/25
BRAWM, NCT04624906: Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

Active, not recruiting
2
63
Canada
Acalabrutinib, Calquence, Bendamustine, Treanda, Rituximab, Rituxan
Sunnybrook Health Sciences Centre, AstraZeneca
Waldenstrom Macroglobulinemia
12/24
03/30
NCT04115631: A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting
2
360
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Bendamustine, SDX-105, Bendamustine Hydrochloride, Bendamustin Hydrochloride, Bendeka, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Liver Lymphoma, Mantle Cell Lymphoma
12/24
03/25
NCT05336812: Acalabrutinib in Combination with Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Recruiting
2
52
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Ohio State University Comprehensive Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/25
12/25
GUIDANCE-005, NCT06441097: Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Not yet recruiting
2
152
NA
Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, Acalabrutinib, Lenalidomide, Decitabine
Ruijin Hospital
Diffuse Large B-Cell Lymphoma
12/27
12/27
NCT04624633: Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Active, not recruiting
2
60
US
Acalabrutinib, Calquence, Umbralisib, RP5264, Ublituximab, LFB-R603
Jennifer R. Brown, MD, PhD, AstraZeneca, TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
12/23
01/30
SMART STOP, NCT04978584: Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Recruiting
2
60
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Vincristine, Leurocristine, VCR, Vincrystine
M.D. Anderson Cancer Center
Diffuse Large B-Cell Lymphoma
01/25
01/25
NCT04198922: Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Recruiting
2
50
US
Acalabrutinib, 1420477-60-6, ACP-196, Benzamide, Bruton Tyrosine Kinase Inhibitor ACP-196, Questionnaire Administration
Fred Hutchinson Cancer Center, AstraZeneca
Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm
08/25
01/27
NCT04722172: A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

Active, not recruiting
2
55
US
Acalabrutinib, Obinutuzumab
Memorial Sloan Kettering Cancer Center, AstraZeneca, Genentech, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
02/25
02/25
NCT04404088: Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

Active, not recruiting
2
60
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
03/25
03/25
NCT04560322: Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Recruiting
2
40
US
Venetoclax, Venclexta, Obinutuzumab, Gazyva, Acalabrutinib, Calquence
Massachusetts General Hospital, Genentech, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
03/25
03/25
NCT03516617: Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting
2
120
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Laboratory Biomarker Analysis, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Quality-of-Life Assessment, Quality of Life Assessment
Mayo Clinic, National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
03/25
03/26
NCI-2018-01182, NCT03128879: Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

Recruiting
2
90
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Acalabrutinib
M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia
06/25
06/25
NCT04189757: Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma

Active, not recruiting
2
9
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Mantle Cell Lymphoma
06/25
06/25
BGB-3111-215 , NCT04116437: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Recruiting
2
90
US
Zanubrutinib, BGB-3111, BRUKINSA
BeiGene
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
10/25
10/25
REMoDL-A, NCT04546620: Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting
2
453
Europe
R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, R-CHOP + acalabrutinib, Acalabrutinib
University Hospital Southampton NHS Foundation Trust, AstraZeneca
Diffuse Large B Cell Lymphoma
01/27
07/27
STELLAR, NCT03899337: A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome

Recruiting
2
105
Europe
Acalabrutinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Pevanti, Rituximab, Mabthera
University of Birmingham, Bloodwise, Acerta Pharma, LLC
Richter Syndrome
10/25
05/27
NCT04660045: Early Intervention With Acalabrutinib in Patients With High Risk CLL

Withdrawn
2
0
US
Acalabrutinib, CALQUENCE, ACP-196
Weill Medical College of Cornell University, AstraZeneca
Chronic Lymphocytic Leukemia, CLL/SLL
01/26
06/26
SAKK 38/19, NCT04604067: Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Recruiting
2
260
Europe
Acalabrutinib
Swiss Group for Clinical Cancer Research
Diffuse Large B-cell Lymphoma
10/25
12/30
CARAMEL, NCT05004064: Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma

Not yet recruiting
2
26
NA
Acalabrutinib, Rituximab
University College, London, AstraZeneca
Mantle Cell Lymphoma
05/26
05/26
NCT04169737: Acalabrutinib and Venetoclax with or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting
2
168
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
07/26
07/26
NCT04765111: Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Active, not recruiting
2
53
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
M.D. Anderson Cancer Center
Mantle Cell Lymphoma
08/26
08/26
NCI-2023-06838, NCT06054776: Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recruiting
2
40
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, Glofitamab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859, RO 7082859, RO7082859, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
City of Hope Medical Center, National Cancer Institute (NCI)
Mantle Cell Lymphoma
10/26
10/26
NCT05065554: ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Recruiting
2
33
US
Acalabrutinib, Calquence, Rituximab, Rituxan
Shayna Sarosiek, MD, AstraZeneca
IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral
12/26
10/28
ALTAMIRA, NCT05214183: Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
81
Europe, RoW
Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
Nordic Lymphoma Group, AstraZeneca
MCL, Mantle Cell Lymphoma
01/27
01/27
ACRUE, NCT05952024: Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

Recruiting
2
80
US, RoW
Acalabrutinib, CALQUENCE®, Rituximab
AstraZeneca
Diffuse Large B-Cell Lymphoma
08/27
08/27
NCT04402138: Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

Completed
2
15
US
Acalabrutinib, Calquence
SCRI Development Innovations, LLC, Acerta Pharma, LLC
Mantle Cell Lymphoma
04/24
04/24
NCT04941716: Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting
2
20
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Fred Hutchinson Cancer Center, AstraZeneca
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
08/27
08/31
NCT04646395: Study of Acalabrutinib and Tafasitamab in MZL Patients

Active, not recruiting
2
26
Europe
Tafasitamab, MOR00208, Acalabrutinib, Calquence
International Extranodal Lymphoma Study Group (IELSG)
Marginal Zone Lymphoma
09/27
03/28
NCT04548648: A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas

Recruiting
2
16
US
Acalabrutinib, ACP-196, CALQUENCE, Isavuconazole, Cresemba
UNC Lineberger Comprehensive Cancer Center, AstraZeneca
Central Nervous System Lymphoma
02/28
02/33
NCT04523428: REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

Recruiting
2
60
Europe
Venetoclax/Acalabrutinib, Venclexta, Venclyxto
Stichting Hemato-Oncologie voor Volwassenen Nederland
CLL/SLL
12/28
12/32
TrAVeRse, NCT05951959: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

Hourglass Dec 2023 - Dec 2023 : Data from TrAVeRse trial in patients with treatment- naïve mantle cell lymphoma at ASH 2023
Hourglass Jan 2020 - Dec 2020 : From ACE-CL-208 trial in r/r CLL
Active, not recruiting
2
108
Europe, Canada, US, RoW
Acalabrutinib, Acalabrutinib, CALQUENCE, Venetoclax, Rituximab
AstraZeneca
Mantle Cell Lymphoma (MCL)
07/28
07/28
NCT04502394: Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Recruiting
1b/2
84
Europe, US, RoW
KRT-232, acalabrutinib, ACP-196
Kartos Therapeutics, Inc.
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
10/22
03/24
ARIA, NCT05205252: A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Calendar Jan 2023 - Dec 2024: Data from trial for hematological malignancies
Withdrawn
1b/2
156
US
Tazemetostat, IPN60200, Tafasitamab, Lenalidomide, Acalabrutinib, Bruton tyrosine kinase inhibitor, Daratumumab (Intravenously), Mosunetuzumab, Daratumumab (Subcutaneously), Hyaluronidase-Fihj, Pomalidomide, Dexamethasone 20mg
Epizyme, Inc.
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
07/23
07/23
2016-003736-21: Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed/Refractory B-cell Malignancies

Not yet recruiting
1/2
71
Europe
Acalabrutinib, AZD2014 Film-Coated Tablet 25mg, AZD2014 Film-Coated Tablet 35mg, AZD2014 Film-Coated Tablet 50mg, ACP-196, AZD2014, Capsule, hard, Film-coated tablet
Acerta Pharma BV, Astra Zeneca
Part 1: De novo Diffuse large B-cell lymphoma (DLBCL), Transformed DLBCL and Richter syndrome (RS).Part 2: De novo Germinal center B-cell (GCB) DLBCL and De novo non-GCB DLBCL, B-cell lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT03205046: A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Checkmark In r/r B-cell malignancies (trial terminated as per sponsor's decision)
Jan 2021 - Jan 2021: In r/r B-cell malignancies (trial terminated as per sponsor's decision)
Hourglass Jan 2019 - Dec 2019 : For r/r B-cell malignancies
Terminated
1/2
25
Europe, US
acalabrutinib, ACP-196, vistusertib, AZD2014
Acerta Pharma BV
DLBCL, Richter Syndrome
11/19
11/19
ACCEPT, NCT03571308 / 2015-003213-18: A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)

Completed
1/2
39
Europe
R-CHOP + acalabrutinib, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisolone, Acalabrutinib
University Hospital Southampton NHS Foundation Trust
Non Hodgkin Lymphoma
01/20
08/23
2019-000111-84: A study of Acalabrutinib alone, or in combination with Rituximab and Lenalidomide for subjects with B-cell Non Hodgkin Lymphoma Studio di acalabrutinib da solo o in associazione con Rituximab e Lenalidomidein soggetti con linfoma non Hodgkin a cellule B

Not yet recruiting
1/2
120
Europe
Acalabrutinib, Rituximab, Revlimid®, Revlimid, [ACP-196], [Rituximab], [Revlimid®], [Revlimid], Capsule, hard, Concentrate for solution for infusion, MabThera, Revlimid®
ACERTA PHARMA BV, Acerta Pharma BV
B-cell Non-Hodgkin Lymphoma Linfoma Non-Hodgkin a cellule B, B-cell Non-Hodgkin Lymphoma Linfoma Non-Hodgkin a cellule B, Diseases [C] - Cancer [C04]
 
 
NCT02328014: Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Hourglass Jan 2020 - Dec 2020 : In B-cell malignancies
Active, not recruiting
1/2
40
US
Acalabrutinib, ACP-196, ACP-319
Acerta Pharma BV, AstraZeneca
Non-Hodgkins Lymphoma, Multiple Myeloma, B-All
06/20
04/26
ACE-ST-209, NCT02586857: A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Hourglass Feb 2019 - Jun 2019 : Data from P1b/2 trial in patients with recurrent GBM who have progressed after 1 or 2 prior systemic treatment regimens
Active, not recruiting
1/2
24
US
ACP-196, Acalabrutinib.
Acerta Pharma BV
Glioblastoma Multiforme
06/20
12/25
KEYNOTE145, NCT02362035: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Checkmark Data from KEYNOTE145 trial in hematological malignancies
Jan 2023 - Jan 2023: Data from KEYNOTE145 trial in hematological malignancies
Active, not recruiting
1/2
161
US
Acalabrutinib, ACP-196, Pembrolizumab, KEYTRUDA
Acerta Pharma BV, Merck Sharp & Dohme LLC
Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia, Multiple Myeloma, Hodgkin Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphomas, Mediastinal Large B Cell Lymphoma, Hairy Cell Leukemia
07/20
04/26
ACE-CL-001, NCT02029443 / 2014-000440-15: ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Checkmark Presentation of data from Phase 1/2 trial in 1L CLL at ASH 2022
Nov 2022 - Nov 2022: Presentation of data from Phase 1/2 trial in 1L CLL at ASH 2022
Checkmark Data from ACE-CL-001 trial for treatment-naive CLL at EHA 2020
Jun 2020 - Jun 2020: Data from ACE-CL-001 trial for treatment-naive CLL at EHA 2020
Checkmark Data from CL-001 trial for treatment-naive CLL at ASCO 2020
More
Active, not recruiting
1/2
306
Europe, US
Acalabrutinib, ACP-196
Acerta Pharma BV
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
07/21
09/27
NCT04419389: APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

Terminated
1/2
1
US
APR-246 (eprenetapopt) + Acalabrutinib in CLL, APR-246 (eprenetapopt) + Venetoclax + Rituximab in CLL, APR-246 (eprenetapopt) + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT, APR-246 (eprenetapopt) + Venetoclax + Rituximab in RT
Aprea Therapeutics
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
08/21
08/21
NCT03932331: Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

Calendar Jan 2024 - Dec 2025: Final data readout from trial for CLL
Hourglass Jan 2023 - Mar 2023 : Second data readout from cohort B of P1/2 trial for CLL
Hourglass Jul 2022 - Dec 2022 : Data from P2 portion of P1/2 trial for MCL
Hourglass Jul 2022 - Sep 2022 : First data readout from cohort B of P1/2 trial for CLL
Hourglass Jul 2022 - Sep 2022 : Final data readout from trial for MCL
Active, not recruiting
1/2
105
RoW
Acalabrutinib
AstraZeneca
Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
12/22
12/23
2020-002464-31: A study to evaluate the safety and efficacy of KRT-232 in combination with Acalabrutinib in patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia. Vizsgálat az acalabrutinibbel együtt adott KRT-232 biztonságosságának és hatásosságának értékelésére relapszált/refrakter diffúz nagy B-sejtes limfómában vagy relapszált/refrakter krónikus limfocitás leukémiában szenvedő betegeknél

Not yet recruiting
1/2
114
Europe, RoW
Acalabrutinib, KRT-232, Tablet, Capsule, hard, CALQUENCE
Kartos Therapeutics Inc., Kartos Therapeutics, Inc, Kartos Therapeutics, Inc.
- Relapsed/Refractory (R/R) de novo TP53 ABC (non-GCB) or GCB diffuse large B-cell lymphoma (DLBCL)- R/R TP53 chronic lymphocytic leukemia (CLL) naïve to prior Bruton's tyrosine kinase (BTK) inhibitor- R/R DLBCL with non-germinal center B-cell like(GCB) subtype- R/R DLBCL with double-expressor lymphoma subtype, - Relapsed/Refractory Diffuse Large B-cell Lymphoma- Relapsed/Refractory Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04]
 
 
ACE-LY-003, NCT02180711: Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Hourglass Feb 2024 - Jun 2024 : Results from ACE-LY-003 trial for r/r follicular lymphoma
Hourglass Jul 2023 - Sep 2023 : Last patient dosing of P1 ACE-LY-003 trial for relapsed/refractory follicular lymphoma
Active, not recruiting
1/2
113
Europe, Canada, US
acalabrutinib, ACP-196, rituximab (IV), Lenalidomide
Acerta Pharma BV, AstraZeneca
Non Hodgkin Lymphoma
08/23
12/28
NCT04630756 / 2020-001642-18: AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

Active, not recruiting
1/2
40
Europe, Canada, US, RoW
AZD4573, AZ13810325, Acalabrutinib, ACP-196 /Calquence
AstraZeneca, Parexel
Advanced Haematological Malignancies
09/23
12/24
NCT05256641: Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Recruiting
1/2
24
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence
Jonsson Comprehensive Cancer Center, AstraZeneca
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Secondary Central Nervous System Lymphoma
10/24
10/25
NCT04906902: Acalabrutinib in CNSL

Recruiting
1/2
49
US
Acalabrutinib, Calquence
Dana-Farber Cancer Institute
Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma, Recurrent Central Nervous System Lymphoma
01/25
01/26
 

Download Options